Ipamorelin Peptide: Research Overview, Purity Data and Where to Buy

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue receptor (GHS-R1a) agonist — a ghrelin mimetic first described in the late 1990s. Laboratory research examines its effects on pulsatile growth hormone release, bone formation, gastrointestinal motility, and appetite-related signaling in animal models and in limited early clinical work. It is supplied for research use only.

What Ipamorelin Is and Where It Came From

Ipamorelin belongs to a family of compounds known as growth hormone secretagogues (GHS): small molecules and short peptides that stimulate growth hormone release through a receptor distinct from the growth hormone-releasing hormone (GHRH) receptor. Structurally it is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, containing several non-proteinogenic and D-amino acid residues that increase resistance to enzymatic degradation compared with an all-L, all-natural sequence. Its commonly cited molecular formula is C38H49N9O5, corresponding to a molecular weight of approximately 712 g/mol. The acetate salt form is the version most often encountered in research supply.

The compound emerged from pharmaceutical discovery work in the 1990s aimed at finding secretagogues with a cleaner endocrine profile than the earlier growth hormone-releasing peptides (GHRP-6, GHRP-2, hexarelin). Those earlier peptides stimulated growth hormone robustly but were also reported to elevate other pituitary and adrenal outputs. Ipamorelin was characterized in early pharmacology as producing growth hormone release with comparatively little concurrent effect on adrenocorticotropic hormone or cortisol in the models tested — the property most often referred to when the compound is described as "selective." That descriptor comes from preclinical characterization rather than from large human trials, and it is worth treating as a model-derived observation rather than a settled clinical fact.

It is useful to place Ipamorelin within its pharmacological neighborhood, because researchers frequently confuse categories that behave quite differently at the receptor level.

Reported Mechanism of Action

Ipamorelin is described in the literature as an agonist at GHS-R1a, a G protein-coupled receptor expressed in the anterior pituitary, hypothalamic nuclei including the arcuate nucleus, and in peripheral tissues such as the enteric nervous system and pancreatic islets. Endogenous acyl-ghrelin is the native ligand for this receptor. Agonist binding is generally reported to couple through Gq and phospholipase C, raising inositol trisphosphate and intracellular calcium in somatotrophs, which promotes exocytosis of stored growth hormone.

Two features of this pathway matter for experimental design. First, GHS-R1a signaling is functionally distinct from — and in several models synergistic with — GHRH receptor signaling, which is why co-administration studies pairing a secretagogue with a GHRH analog appear frequently in the literature and why stacking questions come up so often in applied research settings. Second, growth hormone release remains under negative feedback from somatostatin and from circulating IGF-1, so receptor agonism amplifies pulses within a regulated system rather than overriding it. Chronic-exposure work, including in vitro somatotroph response studies in young female rats, has examined how sustained secretagogue treatment alters pituitary cell behavior over time — an important consideration for any protocol running beyond an acute challenge.

Because GHS-R1a is not confined to the pituitary, the compound's reported effects extend past the somatotropic axis. Enteric receptor populations underlie the gastrointestinal motility literature; hypothalamic populations underlie appetite and energy-balance findings; and islet expression is the presumed basis for observations on insulin secretion.

What the Research Literature Examines

The published evidence base is modest in size, weighted heavily toward animal models, and organized around a handful of distinct research questions. Each area below is summarized at hub level; individual endpoints, timelines, and methodological details are treated in depth in dedicated articles.

Growth hormone secretion and somatotroph biology

The founding research question was whether a compound could stimulate growth hormone release with a narrower endocrine footprint than earlier GHRPs. Rodent work has looked not only at acute hormone output but at what happens to the pituitary itself under chronic secretagogue exposure — for example, examining somatotroph responsiveness in vitro following extended treatment in young female rats. These studies are the foundation for downstream interest in body composition endpoints, but it is a substantial inferential leap from pituitary secretion data to functional outcomes, and readers of this literature should keep that gap in view.

Bone formation and mineral content

Some of the more distinctive findings come from skeletal research. Published rodent studies report that GH secretagogues including Ipamorelin and GHRP-6 increased bone mineral content in adult female rats, and separate work reports that Ipamorelin counteracted a glucocorticoid-induced decrease in bone formation in adult rats. These are mechanistically interesting because they suggest an axis-mediated effect on bone turnover rather than a direct skeletal action. Evidence remains preliminary, confined to animal models, and has not been extended into a substantial human literature.

Gastrointestinal motility and postoperative ileus

This is the area with the most developed translational thread. Preclinical work demonstrated efficacy of Ipamorelin in a rodent model of postoperative ileus, and a prospective, randomized, controlled proof-of-concept study subsequently evaluated the ghrelin mimetic for the management of postoperative ileus in bowel resection patients. A proof-of-concept trial is exactly what its name suggests: a signal-finding exercise, not a definitive efficacy determination. No approved indication followed, and the mechanism — enteric GHS-R1a agonism accelerating gastric emptying and transit — remains an active rather than a resolved research question.

Appetite, cachexia and weight-loss models

Because ghrelin is centrally involved in hunger signaling, GHS-R1a agonists have been examined in models of treatment-associated weight loss. A 2024 study reported that anamorelin and ipamorelin inhibited cisplatin-induced weight loss in ferrets, with anti-emetic effects in that model attributed to a central mechanism for anamorelin specifically. This line of work situates Ipamorelin alongside orally active secretagogues developed for cancer cachexia and illustrates that different GHS-R1a agonists do not necessarily produce identical profiles.

Metabolic and endocrine effects

Investigators have studied the mechanism of Ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats, which is the primary published anchor for questions about glucose handling. Given that growth hormone itself has counter-regulatory effects on insulin sensitivity, the metabolic picture is not reducible to a single direction of effect, and dedicated analyses of insulin sensitivity questions are covered separately.

Reproductive axis and comparative models

Broader endocrine crosstalk has been probed in non-mammalian systems as well — for instance, work examining the influence of ipamorelin acetate on the hypothalamic-pituitary-testicular axis in the cichlid fish Oreochromis mossambicus. Comparative endocrinology of this kind helps map receptor conservation and pathway architecture, though it does not speak directly to mammalian physiology.

Laboratory Handling

Ipamorelin is typically supplied as a lyophilized (freeze-dried) powder in a sealed vial under partial vacuum. In that dry state it is comparatively stable, which is why shipping without cold chain is common practice; the sensitivity begins after reconstitution.

• Reconstitution: laboratories generally introduce sterile diluent slowly down the inner vial wall rather than directly onto the powder cake, then allow dissolution without shaking. Peptides are susceptible to shear and interfacial denaturation, so vigorous agitation is avoided. Gentle swirling until the solution is clear is standard practice.
• Storage of lyophilized material: cool, dark, dry conditions, protected from humidity and repeated temperature swings. Long-term archival storage of unopened vials is normally at freezer temperature.
• Storage after reconstitution: refrigerated, protected from light, and used within a limited working window that depends on diluent choice and whether a bacteriostatic agent is present.
• Freeze-thaw: repeated cycles degrade peptide solutions. Where extended storage of solution is unavoidable, single-use aliquoting is preferred over repeated access to one vial.
• Documentation: recording reconstitution date, diluent, lot number, and storage location keeps results traceable and makes anomalous data interpretable.

Specific concentrations, diluent volumes, and stability windows are covered in the dedicated reconstitution and storage guides rather than here, since they depend on the experimental design and the batch's stated peptide content.

Regulatory and Research-Use Status

Ipamorelin is not an FDA-approved drug in the United States for growth hormone modulation, body composition, bone, gastrointestinal, or any other use discussed on this page. It has not completed the trial program required for approval, and the human data that exist are limited and early-stage. In 2023 the FDA categorized several peptides, including growth hormone secretagogues, in a manner that restricts their use in compounded preparations — a regulatory signal that these molecules sit outside the approved-therapeutics landscape.

Material supplied by research vendors, including Real Peptides, is designated for laboratory research use only. It is not intended for human consumption, veterinary application, diagnostic procedures, or any therapeutic purpose. Institutional research involving vertebrate animals requires appropriate ethical review and approval, and human research requires IRB oversight and applicable regulatory authorization. Nothing in this overview should be read as medical guidance or as an endorsement of any application in people.

How Researchers Evaluate Supplier Quality

Peptide research is unusually vulnerable to material quality problems, because a mislabeled or degraded compound produces data that look real but mean nothing. The following documentation is what serious laboratories request before a batch enters an experiment.

Two practical habits separate careful buyers from casual ones. First, read the chromatogram rather than the headline purity figure — a single sharp peak with a clean baseline tells a different story than a stated percentage with no trace attached. Second, confirm that the lot printed on the vial matches the lot on the certificate. Real Peptides publishes COAs per batch for this reason. Dedicated articles cover how to interpret a COA line by line and how to recognize the documentation patterns typical of counterfeit or under-characterized material.

Where the Open Questions Are

Honest reading of this literature means naming what is not established. Several questions remain genuinely open:

1. Chronic receptor behavior. Whether sustained GHS-R1a agonism produces desensitization, altered somatotroph reserve, or feedback adaptation over extended timeframes is incompletely characterized.
2. Downstream IGF-1 dynamics. Growth hormone pulse amplification does not map linearly onto IGF-1 exposure, and the relationship under repeated secretagogue stimulation deserves more systematic work.
3. Selectivity in humans. The comparatively narrow endocrine profile reported preclinically has not been confirmed across large, well-powered human cohorts.
4. Metabolic net effect. Reported insulin release in rodent pancreas sits alongside growth hormone's counter-regulatory actions; the integrated effect on glucose handling is unresolved.
5. Translation of the GI signal. A single proof-of-concept trial in bowel resection patients is a starting point, not a conclusion, and no confirmatory program has followed publicly.
6. Comparative pharmacology. Differences among GHS-R1a agonists — as seen in the ferret cisplatin work, where anti-emetic effects were attributed specifically to anamorelin — suggest class members are not interchangeable.

For researchers, that combination of a well-defined receptor target and a thin translational evidence base is precisely what makes the compound interesting to study — and precisely why claims about it should stay hedged.

Research-grade Ipamorelin: Real Peptides supplies Ipamorelin for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore Ipamorelin research on Real Peptides

The articles below go deeper on the questions researchers ask most about Ipamorelin.

Research questions

• Does Ipamorelin Cause Insulin Resistance? A Clear Answer
• Does Ipamorelin Cause Water Retention? Our Team Explains
• Does Ipamorelin Cause Hair Loss? Our Team Investigates the Facts
• Ipamorelin Oral Taste — Why It Happens & How To Handle It

Safety & side effects

• Ipamorelin with Coffee Safety — What You Need to Know
• Ipamorelin Air Bubbles Syringe Dangerous? (Safety Facts)

Research timelines & mechanisms

• How Long Ipamorelin Stays in System — Half-Life Explained
• Does Ipamorelin Work for Ghrelin Receptor Studies?

Reconstitution, storage & handling

• How Long Ipamorelin Vial Lasts — Storage Factors
• How to Reconstitute Ipamorelin — Peptide Mixing Guide
• Ipamorelin Left Out Fridge Ruined? Storage Facts
• How to Reconstitute Ipamorelin with Flawless Precision
• How to Store Ipamorelin Long Term — Stability & Handling

Stacks & comparisons

• Ipamorelin Real vs Fake: How to Tell | Real Peptides
• Ipamorelin Quality Real vs Fake — Research Purity Guide
• Can Ipamorelin Be Combined with Other Peptides? (Stacking
• Real Peptides Ipamorelin vs Competitors Quality

Buying & quality

• How to Read Ipamorelin COA — Purity & Potency Decoded
• Best Ipamorelin Supplier Third Party Tested 2026

Legal & regulatory

• Is Ipamorelin Legal? Get the Facts About Its Legality and Status

Ordering Ipamorelin for research

Real Peptides supplies Ipamorelin as a research-use-only reference material: lyophilized powder in a sealed vial, labeled with the lot number that matches its published certificate of analysis. Every batch is tested by an independent laboratory before it ships, and the certificate is published before purchase, so a researcher can read the purity result for the exact lot they are ordering.

• Product page: Ipamorelin for research, with the vial formats currently stocked and the certificate for the batch shipping now.
• Certificates: search any lot number at the certificate lookup; reports stay on file after a batch sells out.
• Shipping: orders dispatch within 24 hours on business days from inventory in Florida and California to every US state; see research peptides by location.
• Related compounds: browse the full research peptide catalog.

Nothing on this page is medical advice or guidance on administering any compound. Ipamorelin is not for human or animal use, and buyers confirm they are 21 or older and purchasing for laboratory research.

Related Ipamorelin Research

For the combined formulation with tesamorelin, see what Tesa/Ipa (tesamorelin and ipamorelin) is.

What does preclinical research report about Ipamorelin and bone tissue?

Bone is a recurring endpoint in growth hormone secretagogue research because the somatotropic axis influences IGF-1 production, osteoblast activity and bone turnover markers. Rodent work examining GHS-R1a agonists has looked at longitudinal bone growth, cortical and trabecular parameters, and mineral content, generally using growth hormone-replete and growth hormone-deficient models to separate direct from axis-mediated effects. Published results in this area are heterogeneous, and findings in one species or skeletal site do not reliably transfer to another.

Laboratories tracking this literature typically follow two related threads: work on bone metabolism, which concentrates on turnover markers and remodelling dynamics, and work on bone density endpoints, which focuses on densitometry and mechanical testing in animal models. Both are discussed alongside broader animal research on growth and recovery.

Because skeletal remodelling occurs over months rather than days, bone-focused investigations depend heavily on extended observation windows, which is why summaries of long-term study designs are relevant here. Short exposure periods rarely produce interpretable skeletal data, and most reviewers treat single-timepoint bone measurements in brief studies as preliminary rather than conclusive. All such work remains preclinical.

What do animal models show about body composition endpoints?

Body composition is one of the most frequently measured outcomes in growth hormone secretagogue research, since growth hormone and IGF-1 influence lipolysis, protein turnover and nitrogen balance. In animal work, investigators typically quantify lean mass, fat mass and organ weights using DEXA, MRI or carcass analysis, with feed intake tracked in parallel because ghrelin-pathway agonists can alter consumption and confound mass measurements.

Published rodent studies on GHS-R1a agonists report variable outcomes depending on species, age, baseline nutritional state and study length, which is why reviewers caution against extrapolating any single dataset. Summaries of body composition research describe how these variables are controlled, while discussions of muscle growth endpoints focus on myofibrillar protein measures and muscle cross-sectional area rather than whole-body mass alone.

Fat-mass endpoints follow a different time course from lean-mass endpoints, a point addressed in reviews of fat-loss result timelines in research models and of muscle growth timelines. None of this work constitutes evidence of outcomes outside controlled laboratory models, and Ipamorelin remains a research chemical with no approved application in composition management.

How long does Ipamorelin remain active after reaching circulation?

Ipamorelin is a small, unmodified pentapeptide, and like most peptides of that size it is cleared relatively quickly by peptidases and renal filtration. Reported elimination parameters vary by species, assay method and matrix, so published half-life figures should be read as model-specific rather than universal. What matters experimentally is that circulating peptide concentration and the downstream hormonal signal follow different curves: the growth hormone pulse it triggers outlasts measurable peptide in plasma, and IGF-1 responses lag further still.

That mismatch is why sampling schedules are designed around the hormone being measured rather than the compound. Overviews of Ipamorelin half-life cover the pharmacokinetic side, while discussions of the growth hormone release timeline address when peak and return-to-baseline values are typically captured.

Route and formulation also influence systemic exposure, a topic addressed in material on bioavailability and absorption. Oral exposure is generally considered impractical for peptides of this structure because of gastric and intestinal degradation. Researchers planning repeat-sampling work usually run a pilot time course in their own model rather than importing values from a different species or analytical platform.

What analytical methods confirm Ipamorelin identity and purity?

Two orthogonal techniques form the backbone of peptide characterization. Reversed-phase high-performance liquid chromatography (RP-HPLC) separates the target peptide from truncated sequences, deletion products, deprotection byproducts and residual scavengers, with purity expressed as the percentage of total peak area at a stated wavelength. Mass spectrometry — usually ESI-MS or MALDI-TOF — then confirms that the dominant peak carries the expected monoisotopic mass for the Aib-His-D-2-Nal-D-Phe-Lys-NH₂ sequence. HPLC alone cannot establish identity, and MS alone cannot quantify impurities; the pair is what makes a certificate of analysis meaningful.

A usable COA states the lot number, the analytical conditions, the gradient or method used, and includes the actual chromatogram and spectrum rather than a summary figure. Guidance on evaluating whether a peptide supplier is legitimate explains how to spot reused or unlabelled documentation.

Additional tests sometimes appear on research-grade documentation: water content by Karl Fischer, residual acetate, and endotoxin screening. Practical walkthroughs in the buying guide for researchers describe how these line items are read, and listings for Ipamorelin for research use should link to lot-matched analytical data.

What happens when Ipamorelin is studied alongside other peptides?

Combination work is common in secretagogue research because the growth hormone axis has two distinct upstream inputs. GHS-R1a agonists such as Ipamorelin act on one pathway, while growth hormone-releasing hormone analogues act on the GHRH receptor; somatostatin tone modulates both. Studies pairing the two classes are designed to test whether the hormonal response is additive, synergistic or simply redundant, and results depend heavily on the model's baseline somatostatin activity and pituitary reserve.

Literature on Ipamorelin combined with other peptides outlines how these designs are structured and why appropriate single-agent control arms are essential. Separate material on research-relevant interactions covers pharmacological variables that can blunt or exaggerate measured responses, including glucocorticoid status and nutritional state.

Non-peptide variables matter as well. Ethanol, for instance, is a known modulator of the somatotropic axis in animal studies, which is why controlled work addresses alcohol-related considerations when it appears in a model system. Reviewers of this literature generally treat multi-agent datasets cautiously: without a factorial design, attributing an observed effect to one component of a combination is not statistically defensible.

Which biomarkers do investigators track in Ipamorelin studies?

Growth hormone itself is pulsatile and short-lived, so single serum measurements are poor indicators of axis activity. Study designs typically combine frequent sampling for growth hormone with a stable downstream integrator — most often IGF-1, sometimes IGFBP-3 — which reflects cumulative exposure over days rather than minutes. Assay platform matters: immunoassay and LC-MS/MS results for growth hormone are not interchangeable, and inter-laboratory variation is a recognized limitation in this field.

Secondary panels frequently include ACTH, cortisol and prolactin, precisely because selectivity relative to other GHRP-class compounds is the claim being tested. Discussions of what Ipamorelin biomarkers reveal and of laboratory values checked before and after exposure describe how these panels are assembled and interpreted.

Metabolic markers such as glucose and insulin are often added because growth hormone influences insulin sensitivity, and bone turnover or inflammatory markers appear in longer studies. Material on downstream effects and research mechanisms connects individual analytes back to receptor-level events. Interpreting any of these values outside a controlled research context is not supported; Ipamorelin is supplied for laboratory use only.

Does circadian timing influence growth hormone data in Ipamorelin studies?

Yes, and it is one of the larger sources of variance in secretagogue research. Endogenous growth hormone secretion is pulsatile and strongly linked to the sleep–wake cycle, with the largest natural pulses occurring during slow-wave sleep in diurnal species. A GHS-R1a agonist introduced near an endogenous pulse produces a different measured response than one introduced during a trough, which is why well-controlled studies fix the time of day across all arms and report it explicitly.

Somatostatin tone oscillates on a similar schedule and acts as the brake on pituitary release, so timing effects are not simply additive. Discussions of sleep-linked growth hormone release timing cover how this interacts with experimental scheduling, and reviews of research on growth hormone release describe the sampling intervals used to capture pulse architecture.

Feeding state is a related confounder, since ghrelin itself rises pre-prandially; overviews of timing and storage considerations address fasted versus fed model conditions. Age is a further modifier, as baseline pulse amplitude declines across the lifespan — a theme examined in literature on Ipamorelin and aging research.

How does Ipamorelin compare with other GHRP-class peptides?

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that belongs to the growth hormone-releasing peptide (GHRP) family, a group that also includes GHRP-2, GHRP-6 and hexarelin. Those earlier compounds trace their structural lineage to met-enkephalin analogues, while Ipamorelin was designed later with the explicit goal of narrowing the hormonal response. The original characterization by Raun and colleagues described it as the first selective growth hormone secretagogue of its class, reporting growth hormone release without a parallel rise in ACTH or cortisol in the preclinical models tested (PubMed (PubMed PMID 9849822)).

That selectivity profile is the main reason investigators separate it from older GHRPs in experimental design, and it is the focus of ongoing work on whether Ipamorelin is the more selective GHRP option. Side-by-side laboratory work is summarized in reviews of comparative studies and research insights, which generally note differences in receptor affinity, signalling bias and secondary endocrine effects rather than differences in the receptor target itself.

Newer secretagogue candidates and non-peptide ghrelin-receptor ligands have entered the research landscape since, and labs mapping the field often consult overviews of alternative research compounds before selecting a reference agonist.

Why is Ipamorelin described as a selective growth hormone secretagogue?

Selectivity, in this context, refers to the breadth of the pituitary response rather than to receptor exclusivity. Ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor identified as the endogenous target of ghrelin, the acylated stomach peptide described by Kojima and colleagues (PubMed (PubMed PMID 10604470)). What distinguishes it in the published record is that growth hormone release occurred in the original preclinical characterization without a corresponding elevation of ACTH or cortisol (PubMed (PubMed PMID 9849822)).

Older GHRP-class compounds and ghrelin itself are frequently reported to produce broader endocrine and appetite-related effects, which complicates interpretation when growth hormone is the endpoint of interest. Researchers studying selective growth hormone release therefore treat Ipamorelin as a comparatively clean probe of the GHS-R1a pathway.

The receptor biology behind that behaviour — Gq coupling, phospholipase C activation, intracellular calcium flux in somatotrophs — is covered in more detail in discussions of the ghrelin receptor mechanism. Because ghrelin signalling also intersects with feeding circuitry, separate literature examines appetite-related observations, which vary considerably across species and model systems.

References

Peer-reviewed sources on Ipamorelin indexed in PubMed, listed for research context. Real Peptides supplies Ipamorelin for laboratory research use only.

1. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior, 2024. PMID 39043357. doi:10.1016/j.physbeh.2024.114644
2. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Animal reproduction science, 2024. PMID 38996787. doi:10.1016/j.anireprosci.2024.107550
3. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease, 2014. PMID 25331030. doi:10.1007/s00384-014-2030-8
4. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 2012. PMID 27186127. doi:10.2147/JEP.S35396
5. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics, 2009. PMID 19289567. doi:10.1124/jpet.108.149211
6. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro endocrinology letters, 2004. PMID 15665799
7. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 2002. PMID 12168778. doi:10.14670/HH-17.707
8. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001. PMID 11735244. doi:10.1054/ghir.2001.0239